PELP1-DT: A Promising Drug Target / Biomarker (G101559451)

Target Name: PELP1-DT

NCBI ID: G101559451

PELP1-DT

Other Name(s): PELP1 divergent transcript

PELP1-DT: A Promising Drug Target / Biomarker

PELP1-DT, also known as protamine-conjugated albumin, is a protein that is expressed in the human body and has been shown to play a role in various physiological processes. One of the most interesting aspects of PELP1-DT is its potential as a drug target or biomarker. In this article, we will explore the biology and potential applications of PELP1-DT in more detail.

The Importance of PELP1-DT

PELP1-DT is a member of the PELP1 gene family, which is responsible for the production of a variety of proteins that play important roles in various physiological processes. One of the most well-studied proteins in this family is PELP1-DT, which is also known as protamine-conjugated albumin.

PELP1-DT is a 14kDa protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidney. It is primarily localized to the liver, where it is involved in the regulation of protein synthesis and metabolism.

One of the most interesting aspects of PELP1-DT is its ability to interact with a variety of different molecules. For example, PELP1-DT has been shown to interact with proteins involved in cell signaling, such as tyrosine kinase, G protein-coupled receptor, and ion channels. This interaction between PELP1-DT and these molecules suggests that it may play a role in the regulation of cellular processes that are important for human health and disease.

PELP1-DT as a Drug Target

The potential use of PELP1-DT as a drug target is one of the most promising aspects of its biology. By targeting PELP1-DT, researchers may be able to manipulate its activity and potentially treat a variety of different diseases.

One of the most promising strategies for targeting PELP1-DT is to use small molecules, such as drugs that bind specifically to its active site. This approach has been used to develop a variety of drugs that are designed to target proteins involved in various cellular processes, including signaling pathways, DNA replication, and metabolism.

Another approach to targeting PELP1-DT is to use antibodies that are designed to recognize and selectively bind to PELP1-DT. This approach has been used to develop antibodies that are specific for a variety of different proteins, including PELP1-DT.

PELP1-DT as a Biomarker

PELP1-DT has also been shown to have potential as a biomarker for a variety of different diseases. For example, some studies have suggested that PELP1-DT may be involved in the development of certain types of cancer, such as liver cancer.

In addition to its potential as a biomarker, PELP1-DT may also be used as a diagnostic tool for certain diseases. For example, some researchers have suggested that PELP1-DT may be expressed in the liver, which could be an indicator of liver disease.

Conclusion

PELP1-DT is a protein that has been shown to play a role in various physiological processes, and its potential as a drug target or biomarker is a promising area of research. Further studies are needed to fully understand the biology and potential applications of PELP1-DT, and to develop treatments that can effectively target its activity.

Protein Name: PELP1 Divergent Transcript

The "PELP1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PELP1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets